A triple receptor agonist at the frontier of GLP-1 metabolic research. RTA is a GLP-1/GIP/glucagon triple receptor co-agonist being actively researched for its metabolic effects, with published clinical data showing significant outcomes in body composition studies.
Key Research Areas
GLP-1/GIP/glucagonMetabolic researchBody compositionTriple receptor agonism
Molecular Information
| Dosage | 10mg, 30mg, 60mg per vial |
| Purity | 99%+ (HPLC & MS Verified) |
| Format | Lyophilized powder |
| Storage | Store at -20°C. Stable at room temperature for short-term shipping. |
| Reconstitution | Reconstitution Solution (for research use only) |
| Verification | NFC Blockchain Tag included |
GLP-RTA is a research compound with a growing body of published literature examining its biological activity and mechanisms of action. The research summaries below are derived from publicly available peer-reviewed studies and are provided for informational purposes only.
Research Focus Areas
GLP-1/GIP/glucagonMetabolic researchBody compositionTriple receptor agonism
Published research on GLP-RTA spans multiple model systems and research frameworks. Studies have examined mechanisms at the molecular, cellular, and systemic levels. Researchers are encouraged to access primary literature through PubMed and peer-reviewed databases.
Research Disclaimer: The research summaries provided are for informational purposes only and are based on publicly available scientific literature. We do not make medical or therapeutic claims. These statements have not been evaluated by the FDA.
Every batch of GLP-RTA is independently tested and shipped with a Certificate of Analysis documenting purity, identity, batch number, and testing methodology.
Testing Specifications
| Testing Method | HPLC + Mass Spectrometry |
| Purity Standard | 99%+ |
| Lab | Third-party independent laboratory (USA 🇺🇸) |
